HRMY Relative Valuation
HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRMY is overvalued; if below, it's undervalued.
Historical Valuation
Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.27 is considered Undervalued compared with the five-year average of 18.52. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 41.57 to 108.35 according to relative valuation methord. Compared to the current price of 38.25 USD , Harmony Biosciences Holdings Inc is Undervalued By 7.99%.
Relative Value
Fair Zone
41.57-108.35
Current Price：38.25
7.99%
Undervalued
10.27
PE
1Y
3Y
5Y
Trailing
Forward
5.78
EV/EBITDA
Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBITDA of 5.78. The 5-year average EV/EBITDA is 10.34. The thresholds are as follows: Strongly Undervalued below 0.92, Undervalued between 0.92 and 5.63, Fairly Valued between 15.06 and 5.63, Overvalued between 15.06 and 19.77, and Strongly Overvalued above 19.77. The current Forward EV/EBITDA of 5.78 falls within the Historic Trend Line -Fairly Valued range.
5.36
EV/EBIT
Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBIT of 5.36. The 5-year average EV/EBIT is 12.09. The thresholds are as follows: Strongly Undervalued below -0.04, Undervalued between -0.04 and 6.03, Fairly Valued between 18.16 and 6.03, Overvalued between 18.16 and 24.23, and Strongly Overvalued above 24.23. The current Forward EV/EBIT of 5.36 falls within the Undervalued range.
2.21
PS
Harmony Biosciences Holdings Inc. (HRMY) has a current PS of 2.21. The 5-year average PS is 4.01. The thresholds are as follows: Strongly Undervalued below 0.53, Undervalued between 0.53 and 2.27, Fairly Valued between 5.75 and 2.27, Overvalued between 5.75 and 7.48, and Strongly Overvalued above 7.48. The current Forward PS of 2.21 falls within the Undervalued range.
6.50
P/OCF
Harmony Biosciences Holdings Inc. (HRMY) has a current P/OCF of 6.50. The 5-year average P/OCF is 12.42. The thresholds are as follows: Strongly Undervalued below -1.08, Undervalued between -1.08 and 5.67, Fairly Valued between 19.17 and 5.67, Overvalued between 19.17 and 25.93, and Strongly Overvalued above 25.93. The current Forward P/OCF of 6.50 falls within the Historic Trend Line -Fairly Valued range.
8.19
P/FCF
Harmony Biosciences Holdings Inc. (HRMY) has a current P/FCF of 8.19. The 5-year average P/FCF is 12.24. The thresholds are as follows: Strongly Undervalued below 3.68, Undervalued between 3.68 and 7.96, Fairly Valued between 16.52 and 7.96, Overvalued between 16.52 and 20.80, and Strongly Overvalued above 20.80. The current Forward P/FCF of 8.19 falls within the Historic Trend Line -Fairly Valued range.
Harmony Biosciences Holdings Inc (HRMY) has a current Price-to-Book (P/B) ratio of 2.64. Compared to its 3-year average P/B ratio of 3.86 , the current P/B ratio is approximately -31.70% higher. Relative to its 5-year average P/B ratio of 8.16, the current P/B ratio is about -67.68% higher. Harmony Biosciences Holdings Inc (HRMY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 10.54%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.50% , the current FCF yield is about -100.00% lower.
2.64
P/B
Median3y
3.86
Median5y
8.16
13.93
FCF Yield
Median3y
10.54
Median5y
7.50
Competitors Valuation Multiple
The average P/S ratio for HRMY's competitors is 0.00, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 28.71%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HRMY increased by 11.16% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 186.04M to 239.46M.
The secondary factor is the P/E Change, contributed -3.26%to the performance.
Overall, the performance of HRMY in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Harmony Biosciences Holdings Inc (HRMY) currently overvalued or undervalued?
What is Harmony Biosciences Holdings Inc (HRMY) fair value?
How does HRMY's valuation metrics compare to the industry average?
What is the current P/B ratio for Harmony Biosciences Holdings Inc (HRMY) as of Dec 05 2025?
What is the current FCF Yield for Harmony Biosciences Holdings Inc (HRMY) as of Dec 05 2025?
What is the current Forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY) as of Dec 05 2025?